Key Investor Signals
Raised SEK 14.5M led by Lund University's venture arm
LU Ventures and Swedish and international angel investors backed the round announced in April 2026. The financing supports preclinical development of the lead antibody ahead of planned clinical trials in 2028.
Founders named on two patent families covering the core antibody science
Pontus Nordenfelt is an inventor on the M-protein antibody family filed in seven jurisdictions. He and Arman Izadi are inventors on a second family covering antibody hinge engineering.
Demonstrated animal proof of concept with a multi-strain lead
Aventera reports proof of concept in animal models and a lead molecule active across several bacterial strains. Published work behind the program also showed protection in mice.
Other Positive Signals
- CEO Arman Izadi first-authored the published antibody-engineering research, treated infectious-disease patients, and won Lund University's 2025 prize for best medical thesis.
- Appointed former Cantargia CEO Göran Forsberg as chair; he raised around $200M and led several antibody programs into clinical development.
- Preclinical and manufacturing leaders bring experience from Cantargia and Hansa Biopharma.
- Scientific advisers include U.S. National Academy of Sciences members Victor Nizet and Michael Dustin.
- Selected as one of eight companies for the 2026 Medicon Village Investor Panel.
Team
Arman Izadi
CEO and Founder
- Practiced as a physician in the infection ward at Lund University Hospital and completed his Swedish medical internship at Karolinska University Hospital.
- First-authored antibody-engineering studies published in Nature Communications in 2024 and PNAS in 2023.
- Won the Anna-Greta Crafoord Prize for the best 2025 doctoral thesis at Lund University's Faculty of Medicine.
- Named inventor on the patent family covering engineered IgG3 antibodies.
Pontus Nordenfelt
Founder and Chairman of the Scientific Advisory Board
- Associate professor at Lund University and head of the Quantitative Immunobiology research group.
- Senior-authored the 2022 EMBO Molecular Medicine paper describing the human antibody behind Aventera's approach.
- Previously co-founded Cytely, a Lund company developing image-analysis software for cell microscopy.
- Named inventor on the patent families covering antibodies against streptococcal M protein and antibody hinge engineering.
Product
Aventera is developing AV01, a preclinical monoclonal antibody for invasive Group A streptococcal infections. The candidate is based on a human antibody isolated from someone who recovered from severe disease and has been engineered to improve immune-mediated bacterial clearance. Aventera plans to begin clinical trials in 2028.
Marks the bacterium for immune-cell clearance
Group A streptococcus uses its surface M protein to capture antibodies by the wrong end, hiding them from immune cells. Aventera's antibody targets the M protein while leaving its tail exposed, allowing immune cells to recognize and engulf the bacterium.
Engineered for stronger activity across strains
Aventera states that careful target selection produced a lead candidate with broad strain coverage. Published research behind the program found that modifying the antibody's hinge improved immune-cell uptake and protected mice from infection.
Designed for the hospital treatment window
AV01 is intended for intravenous use alongside antibiotics in patients with rapidly progressing invasive disease. Routine Strep A testing can identify the bacterial target quickly, limiting the need for new diagnostic infrastructure.
Market Overview
Invasive Group A streptococcal disease is rare, fast-moving, and frequently life-threatening. Across ten U.S. surveillance areas, incidence rose from 3.6 cases per 100,000 people in 2013 to 8.2 in 2022. Almost every patient was hospitalized, 39.6% required intensive care, and mortality reached 19.5% in the most severe presentations.
Treatment relies on intravenous antibiotics, supportive care, and surgery when tissue is destroyed. Group A strep remains susceptible to penicillin, but resistance to erythromycin and clindamycin is increasing. Aventera is targeting a clearly defined hospital population with no approved targeted therapy and an established route for administering intravenous biologics.
Estimated annual cases over the latest five-year period, causing between 1,800 and 2,400 deaths.
Case-fatality rate for bloodstream infection, septic shock, and streptococcal toxic shock syndrome. Necrotizing fasciitis had a 17.8% case-fatality rate.
Around one-third of invasive infections are caused by bacteria resistant to these two antibiotics. The equivalent share was 12.7% in 2013.
Beyfortus, a monoclonal antibody that prevents severe respiratory infection in infants, generated €1.781B in 2025 sales.
Comparable Outcomes
Cantargia
Cantargia developed CAN10, an antibody targeting IL1RAP for inflammatory diseases. The program had entered first-in-human testing when the transaction was agreed. Otsuka completed the program acquisition in September 2025 for $33M upfront and up to $580M in milestone payments, bringing the total potential value to $613M.
Visterra
Visterra developed antibodies against conserved sites on pathogens. Its lead program targeted hospitalized influenza patients and had reached Phase 2. Otsuka completed the acquisition of Visterra in August 2018 for approximately $430M in cash.
Cubist Pharmaceuticals
Cubist developed and sold Cubicin, a once-a-day intravenous antibiotic for bloodstream infection and severe skin infection caused by Staphylococcus aureus. It had treated more than two million patients by the time of the sale. Merck completed the acquisition of Cubist on 21 January 2015 at an equity valuation of $8.4B.
Interested in More Startups Like Aventera Antibodies?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.